|Videos|September 22, 2017

What Makes ABSSSI Antibiotic Iclaprim Unique?

Author(s)Contagion&reg Editorial Staff

William D. O’Riordan, MD, FACEP, explains what makes iclaprim a unique antibiotic.

William D. O’Riordan, MD, FACEP, chief medical officer, eStudySite, explains how iclaprim has a unique mechanism of action, making it a unique antibiotic to treat acute bacterial skin and skin structure infections. Dr. O’Riordan explains how dihydrofolate reductase interferes with an enzyme that is involved with the bacterial cell and essentially “does away” with it.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Latest CME

Virtual Event

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

July 14, 2026

In-Person + Virtual Event

25th Annual International Congress on the Future of Breast Cancer® West

July 17-18, 2026

Virtual Event

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

2-Part Webinar Series

Virtual Event

Wisconsin Association of Hematology and Oncology

2 Sessions are Available!

Virtual Event

Indiana Oncology Society

2 Sessions are Available!

Virtual Event

Arkansas Association of Cancer Professionals

1 Session is Available!

$(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York$

What Makes ABSSSI Antibiotic Iclaprim Unique?

Related Content

Nutrient-Limited Conditions May Dramatically Alter Antibiotic Effectiveness

During Current Outbreak, bioMérieux Delivers its Ebola Rapid Diagnostics Testing in Central Africa

Susceptible…but Not Responding: When Lab Results Don’t Match the Patient

SNAP Trial Findings Favor Penicillin Over Antistaphylococcal Penicillins for Susceptible Staph Bacteremia

SNAP Global Trial Findings Support Cefazolin for MSSA Bacteremia

Latest CME

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

25th Annual International Congress on the Future of Breast Cancer® West

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Arkansas Association of Cancer Professionals

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Rhode Island Oncology Society

Kentucky Society of Clinical Oncology

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

27th Annual International Lung Cancer Congress®

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Community Practice Connections™: 16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

West Virginia Oncology Society

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)

Tennessee Oncology Practice Society

Colorado Oncology Society

Wyoming State Oncology Society

Montana State Oncology Society

24th Annual International Congress on the Future of Breast Cancer® East

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Arizona Clinical Oncology Society

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Houston Hematology Satellite Symposia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Radioligand Therapy 101: The Science Behind the Strategy

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

26th Annual International Lung Cancer Congress

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

IgAN Case Files: Real Conversations, Evolving Evidence

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia